Manufacturing Partnerships Biodexa's partnership with Syngene demonstrates outsourced manufacturing capability; there is potential to broaden CMO collaborations to scale clinical supply for eRapa and other pipeline assets, enabling faster timelines and cost efficiencies across GI oncology and CNS programs.

Early Access Channel The global Early Access program for FAP signals strong patient demand and market interest; business development can offer enrollment support, supply chain readiness, and regional distribution deals, while partnering with patient groups to accelerate access and generate near-term revenue.

Late-stage Licensing eRapa targeting FAP is positioned for late-stage trials, presenting opportunities for licensing or co-development with larger partners to share development risk and access broader geographies, as well as potential CRO collaboration to execute global trials efficiently.

Strategic Funding With a recent financing and no current revenue, Biodexa may seek strategic investments or milestone-driven partnerships that fund development while granting partners access to its GI oncology and brain cancer programs.

Global Partnering Active engagement in global conferences indicates readiness to engage with a broad partner ecosystem; this can drive deal flow for manufacturing, distribution, and co-development across international markets, as well as visibility to investors.